SCHEMBL2178015

SCHEMBL2178015

CS(=O)(=O)c1ccc(CN2CC3C(C2)C3C(=O)Nc2ccc(N3CCOCC3)c(F)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
SLC6A9 P48067 2/20 0.45
HTT P42858 2/20 0.45
CYP2C9 P11712 1/20 0.45
RAB9A P51151 5/20 0.44
NPC1 O15118 4/20 0.44
MAPT P10636 3/20 0.44
KMT2A Q03164 4/20 0.44
MTOR P42345 2/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPK1 P28482 1/20 0.43
LMNA P02545 2/20 0.41
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2170675 0.89 L3MBTL1 (0.52) L3MBTL1HTTCYP2C9RAB9ANPC1
SCHEMBL4412368 0.89 MAPT (0.53) L3MBTL1HTTCYP2C9RAB9ANPC1
SCHEMBL4417594 0.88 L3MBTL1 (0.48) L3MBTL1HTTCYP2C9RAB9ANPC1
SCHEMBL4418852 0.87 ALDH1A1 (0.49) L3MBTL1HTTCYP2C9RAB9ANPC1
SCHEMBL4415238 0.87 HIF1A (0.52) L3MBTL1HTTCYP2C9RAB9ANPC1
SCHEMBL4423761 0.87 MTOR (0.49) L3MBTL1HTTCYP2C9RAB9ANPC1
SCHEMBL4425268 0.87 L3MBTL1 (0.48) L3MBTL1HTTCYP2C9RAB9ANPC1
SCHEMBL4414283 0.86 MAPT (0.49) L3MBTL1SLC6A9HTTRAB9ANPC1
SCHEMBL4414909 0.86 HIF1A (0.54) L3MBTL1HTTCYP2C9RAB9ANPC1
SCHEMBL4423905 0.86 HTT (0.60) L3MBTL1HTTCYP2C9RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
JP-4732354-B2 2011-07-27 JP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 L3MBTL1 1416/4885SLC6A9 9/4885HTT 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.